



**PRESS RELEASE**  
PledPharma AB

## **PledPharma receives US patent for method of treatment related to calmangafodipir**

***Stockholm, May 11, 2020. PledPharma AB (STO: PLED) has received a notice of allowance from US Patent Office (USPTO) regarding method of treatment claims, forming an additional protective layer around candidate drugs PledOx® and Aladote®.***

The decision from USPTO is based on PledPharma's second patent application with the title "Pharmaceutical Compositions and Therapeutic Methods Employing a Combination of a Manganese Complex Compound and a Non-Manganese Complex Form of the Compound". The expiry date for the patent is July 2030.

"We are pleased with the notice of allowance of our second patent application from the USPTO to further strengthen our robust patent portfolio", said Nicklas Westerholm, CEO, PledPharma.

This second patent family protects against the use of a manganese-containing complex (e.g. mangafodipir) in combination or administered sequentially with a non-manganese complex (e.g. calcium fodipir). This is in addition to the already approved composition-of-matter patent of calmangafodipir for the treatment of e.g. acetaminophen (paracetamol) induced acute liver failure or oxaliplatin induced peripheral nerve damage, with expiry date December 2032.

The patent has previously been approved in Australia, Canada, Europe, India, Israel, Japan, Mexico, Russia, South Africa and South Korea, with July 2030 as its expiry date.

### **For further information, please contact:**

Nicklas Westerholm, CEO

Tel. +46 (0)73 354 20 62

[nicklas.westerholm@pledpharma.se](mailto:nicklas.westerholm@pledpharma.se)

Yilmaz Mahshid, CFO

Tel. +46 (0)72 231 68 00

[Yilmaz.mahshid@pledpharma.se](mailto:Yilmaz.mahshid@pledpharma.se)

*The information was submitted for publication, through the agency of the contact persons set out above, at 2020-05-11, 08:00 CET.*

### **About PledPharma**

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's project **PledOx®** is a first in class drug candidate and is being developed to prevent nerve damage associated with chemotherapy. The phase III program was recently stopped with a data cut-off targeted for the third quarter 2020. The drug candidate **Aladote®** is a first in class drug candidate and is being developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed, and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market. For more information, see <http://www.pledpharma.com/>